Company Statements

02/17/2023

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

02/09/2023

Gilead Sciences Commends Convictions in Counterfeiting Scheme, Pledges Continued Commitment to Protect Patients

12/23/2022

Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities

10/27/2022

Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus

09/28/2022

Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety

08/16/2022

Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5

08/03/2022

Sacituzumab Govitecan-Hziy (Trodelvy®) Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer and Added as a Category 2A Preferred Recommendation for HR+/HER2- Metastatic Breast Cancer in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

07/27/2022

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

06/24/2022

Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade

06/03/2022

All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.

04/21/2022

Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission

03/15/2022

Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products

03/09/2022

Gilead to Expand Footprint in Oceanside

02/08/2022

Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities

02/01/2022

Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare

01/19/2022

Gilead Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply Chain

01/14/2022

Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia

12/17/2021

Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression

12/3/2021

Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates

12/01/2021

Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant

11/23/2021

Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir

10/20/2021

Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union

09/27/2021

Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer

08/09/2021

Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees

08/05/2021

Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States

07/21/2021

Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis

07/02/2021

Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)

04/21/2021

Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer

04/12/2021

Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19

04/09/2021

Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

04/08/2021

Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

02/09/2021

Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services

02/07/2021

Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD

01/13/2021

Gilead Sciences Statement on Recent Events in Washington, D.C.

12/21/2020

Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®

11/19/2020

Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines

10/15/2020

Gilead Sciences Statement on the Solidarity Trial

09/23/2020

Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations

09/23/2020

Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines

08/06/2020

Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network

08/05/2020

Gilead Sciences Statement on State Attorneys General Letter on Remdesivir

07/08/2020

Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19

06/17/2020

Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19

06/01/2020

Gilead Sciences Statement on Remdesivir Clinical Data

05/29/2020

Gilead Sciences Response to U.S. Senators on Trial Diversity

05/22/2020

Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study

05/05/2020

Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

04/24/2020

Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

04/23/2020

Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

04/10/2020

Gilead Sciences Response to Médecins Sans Frontières

03/25/2020

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

03/23/2020

Gilead Sciences Statement on Ensuring Continued  Supply of HIV Medicine Amid Coronavirus Outbreak

03/22/2020

Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

02/05/2020

Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

01/31/2020

Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

12/03/2019

Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females

11/07/2019

Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

08/21/2019

Petitions to US Patent and Trademark Office on HIV PrEP Patents

06/11/2019

Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

05/14/2019

Gilead Sciences Statement On Inaccurate Reporting On Truvada®

04/10/2019

Gilead Sciences Statement on Commitment to Providing Price Information

04/04/2019

Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

04/03/2019

Gilead Sciences Announces $500,000 Grant To Pan American Development Foundation To Provide Emergency Health Services For Venezuelan Migrants And Host Communities In Colombia

09/27/2018

Gilead Sciences Statement on Grants to Spouses of Caricom Leaders Action Network (SCLAN) to Expand Access to Youth HIV Prevention and Care in the Caribbean

09/24/2018

A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV

09/07/2018

Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries

05/02/2018

Gilead Publishes 2017 Year in Review

11/09/2017

Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index

09/01/2017

Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

05/01/2017

Gilead Publishes Year in Review 2016

12/06/2016

Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report

12/01/2016

Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries

11/11/2016

Statement on DISCOVER Study of F/TAF for PrEP

08/01/2016

Gilead Publishes 2015 Corporate Social Responsibility Report

08/14/2015

Gilead Supports PrEP Education to Increase HIV Prevention and Awareness

08/12/2015

Gilead Publishes Its 2014 Corporate Contributions Report